Orion Corporation: Managers’ transactions – Mikael Silvennoinen

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

ORION CORPORATION
MANAGERS’ TRANSACTIONS
11 MAY 2023 at 15.30 EEST
        

Orion Corporation: Managers’ transactions – Mikael Silvennoinen

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Orion Oyj – Managers’ Transactions
____________________________________________
Person subject to the notification requirement
Name: Mikael Silvennoinen
Position: Member of the Board/Deputy member
Issuer: Orion Oyj
LEI: 74370029VAHCXDR7B745
Notification type: INITIAL NOTIFICATION
Reference number: 31448/5/6

____________________________________________
Transaction date: 2023-05-09
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
ISIN: FI0009014377
Nature of transaction: DISPOSAL

Transaction details
(1): Volume: 461 Unit price: 43.3 EUR
(2): Volume: 642 Unit price: 43.3 EUR

Aggregated transactions (2):
Volume: 1103 Volume weighted average price: 43.3 EUR
____________________________________________
Transaction date: 2023-05-09
Venue: CEUX
Instrument type: SHARE
ISIN: FI0009014377
Nature of transaction: DISPOSAL

Transaction details
(1): Volume: 280 Unit price: 43.3 EUR
(2): Volume: 36 Unit price: 43.3 EUR
(3): Volume: 340 Unit price: 43.3 EUR

Aggregated transactions (3):
Volume: 656 Volume weighted average price: 43.3 EUR

Orion Corporation

Liisa Hurme

President and CEO

    Olli Huotari

SVP, Corporate Functions

 

                                                

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion’s net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.

Staff

Recent Posts

Glassbeam Awarded FedRAMP Authorization for its SAAS analytics solution for connected medical systems by the U.S. Department of Veterans Affairs.

This designation enables Glassbeam to support federal government agency customers increase uptime for all MRI…

20 minutes ago

XtalPi Announces Strategic Acquisition of Liverpool ChiroChem (LCC), Unlocking Unprecedented Power in Chemical Space Exploration

CAMBRIDGE, Mass. and LIVERPOOL, United Kingdom, June 13, 2025 /PRNewswire/ -- XtalPi, a leading life…

20 minutes ago

Mitsubishi Research Institute and Astellas Announce Collaboration to Support Pharma Startups in Japan

Accelerating the Growth of Globally Active Drug-Discovery Startups from Japan TOKYO, June 13, 2025 /PRNewswire/…

20 minutes ago

Maria Ansari, MD, FACC, named to Modern Healthcare’s list of 50 Most Influential Clinical Executives

Co-CEO of The Permanente Federation and leader of multiple Permanente Medical Groups at Kaiser Permanente,…

12 hours ago

Dignify Therapeutics Announces Jeff Welch as Chief Operating Officer

RESEARCH TRIANGLE PARK, N.C., June 12, 2025 /PRNewswire/ -- Dignify Therapeutics (Dignify), a pharmaceutical and medical…

12 hours ago

Transforming Communication in the Workplace and Beyond: Glodean Champion Launches “The Process to LOVE™” – A Revolutionary Communication Framework for Human-Centered Leadership

CHICAGO, June 12, 2025 /PRNewswire/ -- Workplace miscommunication costs businesses an estimated $1.2 trillion annually and…

12 hours ago